Answers are grounded in this paper and cite their sources.
Background Pembrolizumab (PB), a PD-1 immune checkpoint inhibitor, and enfortumab vedotin (EV), a Nectin-4 targeting antibody-drug conjugate delivering the microtubule-disrupting payload MMAE, represent the current standard of care for advanced urothelial carcinoma. While PB-associated glomerulopathy is a recognized rare complication, collapsing glomerulopathy with nephrotic-range proteinuria developing approximately five weeks after starting combination EV and PB, along with subsequent progression to kidney failure in a patient with advanced pre-existing chronic kidney disease (CKD) to our knowledge, has not been previously described. Case presentation A 76-year-old male with high-grade urothelial carcinoma and baseline CKD G4 (eGFR 25 mL/min/1.73 m 2 , creatinine 2.5 mg/dL, proteinuria 2.1 g/24 h), attributed to diabetes, hypertension, and prior cisplatin-based chemotherapy, was started on PB 200 mg IV and EV 1 mg/kg IV on a 21-day cycle. Approximately five weeks after starting therapy, he developed AKI presenting with a creatinine of 3.1 mg/dL, eGFR of 20 mL/min/1.73 m 2 , and nephrotic-range proteinuria of 13.1 g/24 hours. Both agents were discontinued, and empiric corticosteroids were given. Kidney biopsy then showed collapsing focal segmental glomerulosclerosis (cFSGS) in 20% of glomeruli, with 53% global glomerulosclerosis and 70% interstitial fibrosis and tubular atrophy. Kidney function did not improve with corticosteroids or subsequent rituximab. Eleven months after starting therapy, he required hemodialysis (creatinine 8.4 mg/dL, eGFR 6 mL/min/1.73 m²) and remains dialysis-dependent. Discussion/conclusion This case highlights three key teaching points. First, advanced pre-existing CKD may increase the risk of irreversible progression after cFSGS following ADC-immunotherapy, underscoring the need for baseline nephrology evaluation in this population. Second, the hypothesized interaction between pembrolizumab-associated podocyte dedifferentiation and MMAE-mediated cytotoxicity could help explain why this combination may be hazardous to a compromised kidney. This hypothesis, together with the possibility of an ADC payload class effect, warrants investigation as ADC-immunotherapy regimens are more widely adopted. Third, once advanced interstitial fibrosis is established, immunosuppressive salvage is unlikely to alter the trajectory, and its toxicity must be weighed against a low probability of benefit.
No takes yet. Share an insight, caveat, or question.
Hitti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: